Opening Ceremony + Plenary Session 1: Post-pandemic construction of health product market transparency, efficiency and fairness – WHO

Opening Ceremony + Plenary Session 1: Post-pandemic construction of health product market transparency, efficiency and fairness

Opening Ceremony:

Opening remarks from our distinguished panel of speakers.

Plenary Session 1:

The emergency phase of the COVID-19 pandemic is now officially behind us, but the world is still grappling with its ongoing risks and impacts. A return to a business-as-usual policy or policy vacuum on market transparency and fair pricing of health products would be a great letdown. This session discusses the need for rebuilding the health systems with a blueprint for political actions and a catalog of policy solutions to improve market transparency and fair pricing of health products.

Session Material:

⬇️ PL1_session_slides_combined

⬇️ PL1_Ellen ‘t Hoen

⬇️ PL1_Thomas Cueni

⬇️ PL1_questions_answers_and_links

You may also like

Plenary Session 2: Negotiating fair pricing – opportunities, powers, promises

Plenary Session 2: Negotiating fair pricing – opportunities, powers, promises

Plenary Session 3: Optimizing pricing policies and strategies by buyers and sellers—getting it right + Closing Remarks

Plenary Session 3: Optimizing pricing policies and strategies by buyers and sellers—getting it right + Closing Remarks

Parallel Session 1: Improving market transparency of health products: where to from now?

Parallel Session 1: Improving market transparency of health products: where to from now?

Parallel Session 2: Strengthening pharmaceutical supply resilience for times of crisis: ensuring access and affordability

Parallel Session 2: Strengthening pharmaceutical supply resilience for times of crisis: ensuring access and affordability

Parallel Session 3: Using real-world evidence in the real world: are regulatory and pricing decisions better aligned with health system goals?

Parallel Session 3: Using real-world evidence in the real world: are regulatory and pricing decisions better aligned with health system goals?

Parallel Session 4: The untapped potential of biosimilars: how to ensure affordable access?

Parallel Session 4: The untapped potential of biosimilars: how to ensure affordable access?

Parallel Session 5: Advancing accessibility and affordability of medical devices and in vitro diagnostics by bridging the information gap and complexity

Parallel Session 5: Advancing accessibility and affordability of medical devices and in vitro diagnostics by bridging the information gap and complexity

Parallel Session 6: How to pay for universal access to medicines for rare diseases and by whom? The great conundrum

Parallel Session 6: How to pay for universal access to medicines for rare diseases and by whom? The great conundrum

Parallel Session 7: Using HTA to improve affordable access to essential medicines

Parallel Session 7: Using HTA to improve affordable access to essential medicines

Parallel Session 8: Intellectual property challenges to promote innovation and timely global equitable access and affordability

Parallel Session 8: Intellectual property challenges to promote innovation and timely global equitable access and affordability

Page 1 of 2